JP2022529208A5 - - Google Patents
Info
- Publication number
- JP2022529208A5 JP2022529208A5 JP2021556884A JP2021556884A JP2022529208A5 JP 2022529208 A5 JP2022529208 A5 JP 2022529208A5 JP 2021556884 A JP2021556884 A JP 2021556884A JP 2021556884 A JP2021556884 A JP 2021556884A JP 2022529208 A5 JP2022529208 A5 JP 2022529208A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/364,063 | 2019-03-25 | ||
| US16/364,063 US11033544B2 (en) | 2019-03-25 | 2019-03-25 | Low-dose triple combination formulation |
| PCT/IB2020/000214 WO2020194052A1 (en) | 2019-03-25 | 2020-03-25 | Low-dose triple combination formulation |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022529208A JP2022529208A (ja) | 2022-06-20 |
| JPWO2020194052A5 JPWO2020194052A5 (https=) | 2023-04-05 |
| JP2022529208A5 true JP2022529208A5 (https=) | 2023-04-05 |
| JP7586830B2 JP7586830B2 (ja) | 2024-11-19 |
Family
ID=72606637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021556884A Active JP7586830B2 (ja) | 2019-03-25 | 2020-03-25 | 低用量の三重複合製剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US11033544B2 (https=) |
| EP (1) | EP3946344A4 (https=) |
| JP (1) | JP7586830B2 (https=) |
| KR (1) | KR20220004027A (https=) |
| CN (2) | CN113924096A (https=) |
| AU (2) | AU2020247542A1 (https=) |
| BR (1) | BR112021018994A2 (https=) |
| CA (1) | CA3134800A1 (https=) |
| MX (2) | MX2021011746A (https=) |
| TW (2) | TW202102209A (https=) |
| WO (1) | WO2020194052A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11033544B2 (en) * | 2019-03-25 | 2021-06-15 | The George Institute for Global Health | Low-dose triple combination formulation |
| KR102853692B1 (ko) * | 2021-07-08 | 2025-09-02 | 한미약품 주식회사 | 시타글립틴, 다파글리플로진 및 메트포르민을 포함하는 경구용 복합정제 |
| EP4415723A4 (en) * | 2021-10-12 | 2025-09-03 | Unison Pharmaceuticals Pvt Ltd | PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF SITAGLIPTIN AND EMPAGLIFLOZIN |
| TR2023001202A1 (tr) * | 2023-02-02 | 2024-08-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Fi̇lm kapli empagliflozin ve metformin hi̇droklorür tabletleri̇ |
| KR20260000968A (ko) * | 2024-06-26 | 2026-01-05 | 주식회사 종근당 | 제2형 당뇨병 치료용 조성물, 조합물 및 병용 요법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR065809A1 (es) * | 2007-03-22 | 2009-07-01 | Bristol Myers Squibb Co | Formulaciones farmaceuticas que contienen un inhibidor sglt2 |
| BRPI1008560B1 (pt) * | 2009-02-13 | 2021-08-31 | Boehringer Ingelheim International Gmbh | Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dpp-iv e opcionalmente um outro agente antidiabético e usos dos mesmos |
| EP3142661B1 (en) * | 2014-05-16 | 2021-10-06 | Astrazeneca AB | Method for suppressing glucagon secretion of an sglt2 inhibitor |
| US20160067217A1 (en) * | 2014-09-09 | 2016-03-10 | ARKAY Therapeutics, LLC | Metabolic syndrome treatment |
| US11033544B2 (en) * | 2019-03-25 | 2021-06-15 | The George Institute for Global Health | Low-dose triple combination formulation |
-
2019
- 2019-03-25 US US16/364,063 patent/US11033544B2/en active Active
-
2020
- 2020-03-25 MX MX2021011746A patent/MX2021011746A/es unknown
- 2020-03-25 CA CA3134800A patent/CA3134800A1/en active Pending
- 2020-03-25 KR KR1020217033517A patent/KR20220004027A/ko active Pending
- 2020-03-25 TW TW109110099A patent/TW202102209A/zh unknown
- 2020-03-25 CN CN202080038969.1A patent/CN113924096A/zh active Pending
- 2020-03-25 TW TW114106241A patent/TW202545526A/zh unknown
- 2020-03-25 AU AU2020247542A patent/AU2020247542A1/en not_active Abandoned
- 2020-03-25 BR BR112021018994A patent/BR112021018994A2/pt unknown
- 2020-03-25 WO PCT/IB2020/000214 patent/WO2020194052A1/en not_active Ceased
- 2020-03-25 CN CN202411820468.5A patent/CN119607213A/zh active Pending
- 2020-03-25 EP EP20779606.1A patent/EP3946344A4/en active Pending
- 2020-03-25 JP JP2021556884A patent/JP7586830B2/ja active Active
-
2021
- 2021-05-11 US US17/317,614 patent/US20210260056A1/en not_active Abandoned
- 2021-09-24 MX MX2024013504A patent/MX2024013504A/es unknown
- 2021-11-15 US US17/527,087 patent/US20220226317A1/en not_active Abandoned
- 2021-11-15 US US17/527,084 patent/US20220226315A1/en not_active Abandoned
- 2021-11-15 US US17/527,085 patent/US20220226316A1/en not_active Abandoned
-
2025
- 2025-09-03 AU AU2025226705A patent/AU2025226705A1/en active Pending